Morphic Holding logo
Morphic Holding MORF

Quarterly report 2024-Q2
added 07-25-2024

report update icon

Morphic Holding Financial Ratios 2011-2026 | MORF

Annual Financial Ratios Morphic Holding

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-10.0 -27.9 -14.9 -24.6 -7.4 - - - - - - - -

P/S

2909.6 23.3 72.1 24.6 18.9 - - - - - - - -

EPS

-3.6 -1.6 -2.7 -1.5 -2.7 -22.3 - - - - - - -

EV (Enterprise Value)

1.48 B 1.61 B 1.35 B 1.1 B 326 M 56 M 52.9 M - - - - - -

EBITDA per Share

-4.19 -1.64 -2.65 -1.51 -2.87 - - - - - - - -

EV/EBITDA

-13.9 -20.1 -4.8 - - - - - - - -

PEG

- -0.5 0.15 - - - - - - - -

P/B

2.2 4.7 4.2 7.6 2.3 - - - - - - - -

P/CF

-13.5 -16.3 -17.1 -24.1 -7.3 - - - - - - - -

ROE %

-21.82 -16.91 -28.38 -30.99 -30.75 - - - - - - - -

ROA %

-21.05 -16.02 -22.41 -18.57 -17.51 - - - - - - - -

ROCE %

-25.64 -18.16 -28.45 -32.49 -22.16 - - - - - - - -

Current Ratio

28.3 18.9 4.8 2.5 6.9 - - - - - - - -

DSO

- 7.1 88.7 43.8 74.5 - - - - - - - -

Operating Cycle

- 7.1 88.7 43.8 - - - - - - - - -

Cash Conversion Cycle

- 7.1 88.7 43.8 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Morphic Holding

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.15 -0.91 - -0.73 -0.92 -0.9 - -0.78 0.7 -0.85 - -0.69 -0.77 -0.63 -0.57 0.18 -0.52 -0.55 -0.66 -0.3 -4.73 -2.77 -4.27 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- -1.07 - - - -0.97 - -0.8 0.69 -0.85 - -0.67 -0.77 -0.63 -0.56 0.19 -0.52 -0.58 -0.68 -0.31 -5.05 -3.17 -3.26 - -3.28 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-26.15 -22.19 -18.83 -27.05 -30.27 -18.00 -11.35 -18.50 -17.43 -32.34 -20.92 -33.14 -22.30 -25.23 -30.99 -32.84 -42.82 -38.59 -30.75 -6.51 13.25 31.80 50.40 40.23 26.76 14.91 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-25.29 -21.58 -18.26 -25.97 -28.81 -31.53 -23.57 -29.28 -19.35 -25.68 -16.67 -23.99 -16.07 -16.29 -18.57 -19.26 -25.05 -22.32 -17.51 -12.32 -12.47 -11.95 -9.85 -7.03 -3.29 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-31.00 -26.66 -21.59 -30.22 -32.66 -19.65 -11.94 -19.12 -17.66 -32.46 -20.95 -33.33 -22.71 -26.02 -32.49 -34.71 -45.16 -41.24 -33.34 -7.38 13.27 32.58 51.95 40.59 26.94 15.02 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

23.4 35.6 28.3 36.4 38.7 28.6 18.9 16.1 - 4.7 4.8 5.0 4.8 5.1 2.5 2.5 2.5 2.5 2.3 2.3 2.3 2.3 1.9 1.9 1.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - 84.2 - 14.7 1.5 83.2 - 57.4 48.3 140.8 113.1 25.9 86.8 87.9 - 55.8 56.8 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - 84.2 - 14.7 1.5 83.2 - 57.4 48.3 140.8 113.1 25.9 86.8 87.9 - 55.8 56.8 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - 84.2 - 14.7 1.5 83.2 - 57.4 48.3 140.8 113.1 25.9 86.8 87.9 - 55.8 56.8 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Morphic Holding, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AbbVie AbbVie
ABBV
$ 208.84 - $ 369 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.52 - $ 1.05 B canadaCanada